Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5321515 | 0.89 | SMN1; SMN2 (0.42) | CNR1CNR2USP30OPRK1BTK | |
| SCHEMBL5321509 | 0.89 | SMN1; SMN2 (0.42) | CNR1CNR2USP30OPRK1BTK | |
| SCHEMBL5324440 | 0.83 | RAB9A (0.41) | CNR1CNR2USP30OPRK1ALDH1A1 | |
| SCHEMBL5469398 | 0.83 | RAB9A (0.41) | CNR1CNR2USP30OPRK1ALDH1A1 | |
| SCHEMBL5321750 | 0.83 | OPRK1 (0.49) | OPRK1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5321756 | 0.83 | OPRK1 (0.49) | OPRK1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20292921 | 0.80 | PBK (0.39) | CNR1CNR2BTK | |
| SCHEMBL20292916 | 0.80 | PBK (0.39) | CNR1CNR2BTK | |
| SCHEMBL6365479 | 0.79 | CNR1 (0.51) | CNR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6365484 | 0.79 | CNR1 (0.51) | CNR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208001-A1 | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | INCYTE CORPORATION | 2007-09-06 | — | — | US | disclosed |
| US-20070060480-A1 | Heteroaroyl-substituted phenylalanineamides | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208001-A1 | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | HSD11B1, HSD17B1, HSD3B1 | CNR1 2132/4885CNR2 3450/4885USP30 1314/4885 |
| US-20070060480-A1 | Heteroaroyl-substituted phenylalanineamides | PAH, PM20D2, FARSA | CNR1 2684/4885CNR2 2586/4885USP30 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.